A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia

Condition(s) targeted: Erectile Dysfunction

Intervention: LEVITRA (vardenafil) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, MBBCh MPH, Study Director, Affiliation: GlaxoSmithKline

This is a study consisting of four periods (screening, run-in, treatment, follow-up). A four-week treatment-free, run-in period where the subject will make at least four attempts at intercourse on four separate days with at least 50% of the attempts must be unsuccessful. During run-in the subjects will be using a stopwatch to measure the time from erection perceived hard enough for penetration until withdrawal from the partner's vagina. Next there are 12 weeks of treatment with either placebo or LEVITRA. Each subject will be required to visit the clinic on 5 occasions over a period of 4 months.

Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Evaluating the Efficacy, Safety, and Duration of Erection of Flexible-Dose Vardenafil Administered for 12 Weeks Compared to Placebo in Subjects With Erectile Dysfunction and Dyslipidemia

Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: EF domain score of the International Index of Erectile Function (IIEF) at randomization and every 4 weeks during therapy Diary response: success of insertion and maintenance recorded at every attempt from randomization through end of treatment

Secondary outcome: Duration of erection and specific diary responses concerning satisfaction: every attempt Response to diary questions and scores for Keep It Simple (KIS): randomization and every 4 weeks Response to Global Assessment Question (GAQ): every 4 weeks

Minimum age: 18 Years. Maximum age: 64 Years. Gender(s): Male.

Criteria:

Inclusion criteria:

- Males with ED for more than six months, according to the NIH Consensus Statement

(inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance).

- Stable heterosexual relationship for more than 6 months.

- The subject must make at least four attempts at sexual intercourse (according to the

question in the subject diary: Was sexual activity initiated with the intention of intercourse?) on four separate days during the untreated baseline period. At least 50% of attempts during this period must be unsuccessful, according to the following questions from the subject diary [at least one question should be answered "No"]: Were you able to achieve at least some erection (some enlargement of the penis)? Were you able to insert your penis into your partner's vagina? Did your erection last long enough for you to have successful intercourse?

- Diagnosis of dyslipidemia treated with a stable dose of a statin for 6 months at Visit

1.

- IIEF-EF domain score of 25 denoting mild to severe ED at Visit 2.

- Documented, dated, written Informed Consent.

Exclusion criteria:

- Premature ejaculator <2 minutes

- Any unstable medical, psychiatric, spinal cord injury, penile anatomical

abnormalities, or substance abuse disorder that MD feels subject will not be able to complete the study.

- Low sexual desire.

- Prior prostatectomy surgery

- Severe chronic or acute liver disease, history of moderate or severe liver impairment

- Clinically significant chronic hematological disease

- Bleeding disorder or significant active peptic ulceration.

- Cardiovascular conditions that prevent sexual activity.

- History of heart attack, stroke, or life-threatening arrhythmia within the prior 6

months.

- hypotension or hypertension at rest.

- cancer within the past 5 years. Use of these medications: nitrates or nitric oxide

donors, anti-androgens, oral or injectable androgens, received any investigational drug (including placebo) within 30 days of screening (Visit 1).

- Use of any treatment for ED within 7 days of screening including oral medications,

vacuum devices, constrictive devices, injections or urethral suppositories.

- Subjects who are taking the following potent inhibitors of cytochrome P-450 3A4.

- Abnormal Laboratory Values:

1. serum total testosterone level >25% below the lower limit of normal

2. serum creatinine >3. 0 mg/dl.

3. AST and/or ALT >3x the upper limit of normal.

GSK Clinical Trials Call Center, Huntsville, Alabama 35801, United States

GSK Clinical Trials Call Center, Fairhope, Alabama 36532, United States

GSK Clinical Trials Call Center, Homewood, Alabama 35209, United States

GSK Clinical Trials Call Center, Phoenix, Arizona 85023, United States

GSK Clinical Trials Call Center, Phoenix, Arizona 85018, United States

GSK Clinical Trials Call Center, Concord, California 94520, United States

GSK Clinical Trials Call Center, Huntington Park, California 90255, United States

GSK Clinical Trials Call Center, Newport Beach, California 92660, United States

GSK Clinical Trials Call Center, Modesto, California 95350, United States

GSK Clinical Trials Call Center, Santa Ana, California 92705, United States

GSK Clinical Trials Call Center, Walnut Creek, California 94598, United States

GSK Clinical Trials Call Center, Orangevale, California 95662, United States

GSK Clinical Trials Call Center, Long Island, California 90806, United States

GSK Clinical Trials Call Center, Wheat Ridge, Colorado 80033, United States

GSK Clinical Trials Call Center, Denver, Colorado 80210, United States

GSK Clinical Trials Call Center, New Britain, Connecticut 06052, United States

GSK Clinical Trials Call Center, Pinecrest, Florida 33156, United States

GSK Clinical Trials Call Center, St. Petersburg, Florida 33710, United States

GSK Clinical Trials Call Center, Ft. Myers, Florida 33916, United States

GSK Clinical Trials Call Center, Tampa, Florida 33761, United States

GSK Clinical Trials Call Center, Orlando, Florida 32803, United States

GSK Clinical Trials Call Center, Coral Gables, Florida 33134, United States

GSK Clinical Trials Call Center, Tampa, Florida 33607, United States

GSK Clinical Trials Call Center, Pembroke Pines, Florida 33024, United States

GSK Clinical Trials Call Center, Aventura, Florida 33180, United States

GSK Clinical Trials Call Center, West Palm Beach, Florida 33401, United States

GSK Clinical Trials Call Center, Sarasota, Florida 34237, United States

GSK Clinical Trials Call Center, N. Miami, Florida 33161, United States

GSK Clinical Trials Call Center, Miami, Florida 33143, United States

GSK Clinical Trials Call Center, Clearwater, Florida 33761, United States

GSK Clinical Trials Call Center, Atlanta, Georgia 30342, United States

GSK Clinical Trials Call Center, Woodstock, Georgia 30189, United States

GSK Clinical Trials Call Center, Dawsonville, Georgia 30534, United States

GSK Clinical Trials Call Center, Roswell, Georgia 30076, United States

GSK Clinical Trials Call Center, Columbus, Georgia 31904, United States

GSK Clinical Trials Call Center, Jeffersonville, Indiana 14130, United States

GSK Clinical Trials Call Center, Evansville, Indiana 47714, United States

GSK Clinical Trials Call Center, Avon, Indiana 46123, United States

GSK Clinical Trials Call Center, Fort Wayne, Indiana 46825, United States

GSK Clinical Trials Call Center, Wichita, Kansas 67207, United States

GSK Clinical Trials Call Center, Lexington, Kentucky 40509, United States

GSK Clinical Trials Call Center, Madisonville, Kentucky 42431, United States

GSK Clinical Trials Call Center, Shreveport, Louisiana 71106, United States

GSK Clinical Trials Call Center, Swansea, Massachusetts 02777, United States

GSK Clinical Trials Call Center, Taunton, Massachusetts 02780, United States

GSK Clinical Trials Call Center, Kalamazoo, Michigan 49009, United States

GSK Clinical Trials Call Center, St. Louis Park, Minnesota 55416, United States

GSK Clinical Trials Call Center, St Louis, Missouri 63117, United States

GSK Clinical Trials Call Center, Omaha, Nebraska 68134, United States

GSK Clinical Trials Call Center, Las Vegas, Nevada 89119, United States

GSK Clinical Trials Call Center, Lawrenceville, New Jersey 08648, United States

GSK Clinical Trials Call Center, New York, New York 10016, United States

GSK Clinical Trials Call Center, West Seneca, New York 14224, United States

GSK Clinical Trials Call Center, Rochester, New York 14609, United States

GSK Clinical Trials Call Center, Winston-Salem, North Carolina 27103, United States

GSK Clinical Trials Call Center, Raleigh, North Carolina 27612, United States

GSK Clinical Trials Call Center, Charlotte, North Carolina 28262, United States

GSK Clinical Trials Call Center, Fayetteville, North Carolina 28304, United States

GSK Clinical Trials Call Center, Shippensburg, Pennsylvania 17257, United States

GSK Clinical Trials Call Center, Nashville, Tennessee 37203, United States

GSK Clinical Trials Call Center, Amarillo, Texas 79106, United States

GSK Clinical Trials Call Center, Salt Lake City, Utah 84107, United States

GSK Clinical Trials Call Center, Norfolk, Virginia 23502, United States

GSK Clinical Trials Call Center, Richmond, Virginia 23294, United States

GSK Clinical Trials Call Center, Seattle, Washington 98166, United States

GSK Clinical Trials Call Center, Menomonee Falls, Wisconsin 53051, United States

GSK Clinical Trials Call Center, Milwaukee, Wisconsin 53209, United States

Starting date: May 2006
Ending date: May 2007
Last updated: April 4, 2008